Tumor-Penetrating Delivery of SiRNA Against TNFα to Human Vestibular Schwannomas

Overview

Journal Sci Rep

Specialty Science

Date 2017 Oct 12

PMID 29018206

Citations 9

Authors

Yin Ren

Jessica E Sagers

Lukas D Landegger

Sangeeta N Bhatia

Konstantina M Stankovic

Affiliations

Soon will be listed here.

Abstract

Vestibular schwannoma (VS) is the most common tumor of the cerebellopontine angle, and it typically presents with sensorineural hearing loss. The genomic landscape of schwannoma is complex and many of the molecules implicated in VS pathogenesis represent targets not amenable to antibody-based or small molecule therapeutics. Tumor-targeted delivery of small interfering RNA (siRNA) therapeutics provides a direct and effective means to interrogate targets while minimizing off-target effects. To establish a preclinical model for therapeutic inhibition of putative targets in VS, archived tumor specimens, fresh tumor cells derived from patients with sporadic VS, and an established schwannoma cell line were screened. Nanoparticles directed by the tumor-homing peptide iRGD were selectively taken up by primary VS cultures in vitro via interactions with αvβ3/β5 integrins and neuropilin-1 (NRP-1). Cellular uptake was inhibited by a neutralizing antibody against αv integrin in a dose-dependent manner. When applied to primary VS cultures, iRGD-targeted nanoparticles delivered siRNA directed against TNFα in a receptor-specific fashion to potently silence gene expression and protein secretion. Taken together, our results provide a proof of principle for tumor-targeted, nanoparticle-mediated delivery of siRNA to VS and establish a novel platform for the development and pre-clinical screening of molecular therapeutics against VS.

Citing Articles

The evolving landscape of NF gene therapy: Hurdles and opportunities.

ODonohue A, Ginn S, Burgio G, Berman Y, Dabscheck G, Schindeler A Mol Ther Nucleic Acids. 2025; 36(1):102475.

PMID: 40034205 PMC: 11872496. DOI: 10.1016/j.omtn.2025.102475.

Tumor biomechanical stiffness by magnetic resonance elastography predicts surgical outcomes and identifies biomarkers in vestibular schwannoma and meningioma.

Duhon B, Thompson K, Fisher M, Kaul V, Nguyen H, Harris M Sci Rep. 2024; 14(1):14561.

PMID: 38914647 PMC: 11196577. DOI: 10.1038/s41598-024-64597-1.

The genetic landscape and possible therapeutics of neurofibromatosis type 2.

Ghalavand M, Asghari A, Farhadi M, Taghizadeh-Hesary F, Garshasbi M, Falah M Cancer Cell Int. 2023; 23(1):99.

PMID: 37217995 PMC: 10204202. DOI: 10.1186/s12935-023-02940-8.

Delivery of Various Cargos into Cancer Cells and Tissues via Cell-Penetrating Peptides: A Review of the Last Decade.

Shoari A, Tooyserkani R, Tahmasebi M, Lowik D Pharmaceutics. 2021; 13(9).

PMID: 34575464 PMC: 8470549. DOI: 10.3390/pharmaceutics13091391.

A Review of Drug Therapy in Vestibular Schwannoma.

Long J, Zhang Y, Huang X, Ren J, Zhong P, Wang B Drug Des Devel Ther. 2021; 15:75-85.

PMID: 33447015 PMC: 7802892. DOI: 10.2147/DDDT.S280069.

References

Boin A, Couvelard A, Couderc C, Brito I, Filipescu D, Kalamarides M . Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. Neuro Oncol. 2014; 16(9):1196-209. PMC: 4136892. DOI: 10.1093/neuonc/nou020. View

McNamara 2nd J, Andrechek E, Wang Y, Viles K, Rempel R, Gilboa E . Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol. 2006; 24(8):1005-15. DOI: 10.1038/nbt1223. View

Poltorak A, He X, Smirnova I, Liu M, Van Huffel C, Du X . Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998; 282(5396):2085-8. DOI: 10.1126/science.282.5396.2085. View

Lim M, Guccione S, Haddix T, Sims L, Cheshier S, Chu P . alpha(v)beta(3) Integrin in central nervous system tumors. Hum Pathol. 2005; 36(6):665-9. DOI: 10.1016/j.humpath.2005.03.014. View

Pasqualini R, Koivunen E, Ruoslahti E . Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 1997; 15(6):542-6. DOI: 10.1038/nbt0697-542. View

Davis M, Zuckerman J, Choi C, Seligson D, Tolcher A, Alabi C . Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature. 2010; 464(7291):1067-70. PMC: 2855406. DOI: 10.1038/nature08956. View

Messerli S, Prabhakar S, Tang Y, Mahmood U, Giovannini M, Weissleder R . Treatment of schwannomas with an oncolytic recombinant herpes simplex virus in murine models of neurofibromatosis type 2. Hum Gene Ther. 2006; 17(1):20-30. DOI: 10.1089/hum.2006.17.20. View

van Wijk F, Staecker H, Keithley E, Lefebvre P . Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss. Audiol Neurootol. 2006; 11(6):357-65. DOI: 10.1159/000095897. View

Havaki S, Kouloukoussa M, Amawi K, Drosos Y, Arvanitis L, Goutas N . Altered expression pattern of integrin alphavbeta3 correlates with actin cytoskeleton in primary cultures of human breast cancer. Cancer Cell Int. 2007; 7:16. PMC: 2116995. DOI: 10.1186/1475-2867-7-16. View

10.

Sugahara K, Teesalu T, Karmali P, Kotamraju V, Agemy L, Greenwald D . Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science. 2010; 328(5981):1031-5. PMC: 2881692. DOI: 10.1126/science.1183057. View

11.

Carson-Walter E, Watkins D, Nanda A, Vogelstein B, Kinzler K, St Croix B . Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res. 2001; 61(18):6649-55. View

12.

Hong S, Leroueil P, Majoros I, Orr B, Baker Jr J, Banaszak Holl M . The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol. 2007; 14(1):107-15. DOI: 10.1016/j.chembiol.2006.11.015. View

13.

Lysaght A, Kao S, Paulo J, Merchant S, Steen H, Stankovic K . Proteome of human perilymph. J Proteome Res. 2011; 10(9):3845-51. PMC: 3179892. DOI: 10.1021/pr200346q. View

14.

Heldin C, Rubin K, Pietras K, Ostman A . High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004; 4(10):806-13. DOI: 10.1038/nrc1456. View

15.

El Badawy A, Luxton T, Silva R, Scheckel K, Suidan M, Tolaymat T . Impact of environmental conditions (pH, ionic strength, and electrolyte type) on the surface charge and aggregation of silver nanoparticles suspensions. Environ Sci Technol. 2010; 44(4):1260-6. DOI: 10.1021/es902240k. View

16.

Edrees A, Misra S, Abdou N . Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions. Clin Exp Rheumatol. 2005; 23(4):469-74. View

17.

Aouadi M, Tesz G, Nicoloro S, Wang M, Chouinard M, Soto E . Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature. 2009; 458(7242):1180-4. PMC: 2879154. DOI: 10.1038/nature07774. View

18.

Teesalu T, Sugahara K, Kotamraju V, Ruoslahti E . C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A. 2009; 106(38):16157-62. PMC: 2752543. DOI: 10.1073/pnas.0908201106. View

19.

Thakur J, Banerjee A, Khan I, Sonig A, Shorter C, Gardner G . An update on unilateral sporadic small vestibular schwannoma. Neurosurg Focus. 2012; 33(3):E1. DOI: 10.3171/2012.6.FOCUS12144. View

20.

Goutagny S, Raymond E, Esposito-Farese M, Trunet S, Mawrin C, Bernardeschi D . Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J Neurooncol. 2015; 122(2):313-20. DOI: 10.1007/s11060-014-1710-0. View